Basics 4D Molecular Therapeutics, Inc. IPO Date: December 11, 2020 Sector: Healthcare Industry: Biotech Market Cap: $524.94M Activated in VL: True Average Daily Range Avg Daily Range: $0.62 | 3.58% Avg Daily Range (30 D): $0.32 | 3.79% Avg Daily Range (90 D): $0.26 | 4.11% Institutional Daily Volume Avg Daily Volume: .42M Avg Daily Volume (30 D): .64M Avg Daily Volume (90 D): .87M Trade Size Avg Trade Size (Sh.): 75 Avg Trade Size (Sh.) (30 D): 82 Avg Trade Size (Sh.) (90 D): 95 Institutional Trades Total Inst.Trades: 1,058 Avg Inst. Trade: $1.86M Avg Inst. Trade (30 D): $2.01M Avg Inst. Trade (90 D): $1.62M Avg Inst. Trade Volume: .11M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.85M Avg Closing Trade (30 D): $.93M Avg Closing Trade (90 D): $1.19M Avg Closing Volume: 101.77K     News Sep 11, 2025 @ 10:00 AM GenVivo Strengthens Oncology Leadership with Appoi... Source: Genvivo, Inc. Aug 11, 2025 @ 12:16 PM 4dMT Revenue Jumps 200 Percent in Q2 Source: Jesterai Aug 11, 2025 @ 12:00 PM 4DMT Reports Second Quarter 2025 Financial Results... Source: 4D Molecular Therapeutics Jul 24, 2025 @ 12:00 PM 4DMT Announces Presentations at 43rd Annual Scient... Source: 4D Molecular Therapeutics May 7, 2025 @ 8:44 AM Gene Therapy in Ophthalmology Industry Report 2025... Source: Researchandmarkets.Com Financials   TTM Q2 2025 Q1 2025 Basic EPS $-3.53 $-.98 $-.86 Diluted EPS $-3.53 $-.98 $-.86 Revenue $ .03M $ .02M $ .01M Gross Profit $ $ $ Net Income / Loss $ -196.14M $ -54.66M $ -47.97M Operating Income / Loss $ -220.33M $ -59.46M $ -53.62M Cost of Revenue $ $ $ Net Cash Flow $ -111.9M $ -72.18M $ M PE Ratio